Objective: The human serum metabolite profile is reflective of metabolic processes, including pathophysiological changes characteristic of diseases. Therefore, investigation of serum metabolite concentrations in obese children might give new insights into biological mechanisms associated with childhood obesity. Methods: Serum samples of 80 obese and 40 normal-weight children between 6 and 15 years of age were analyzed using a mass spectrometry-based metabolomics approach targeting 163 metabolites. Metabolite concentrations and metabolite ratios were compared between obese and normal-weight children as well as between children of different pubertal stages. Results: Metabolite concentration profiles of obese children could be distinguished from those of normal-weight children. After correction for multiple testing, we observed 14 metabolites (glutamine, methionine, proline, nine phospholipids, and two acylcarnitines, p < 3.8 × 10–4) and 69 metabolite ratios (p < 6.0 × 10–6) to be significantly altered in obese children. The identified metabolite markers are indicative of oxidative stress and of changes in sphingomyelin metabolism, in β-oxidation, and in pathways associated with energy expenditure. In contrast, pubertal stage was not associated with metabolite concentration differences. Conclusion: Our study shows that childhood obesity influences the composition of the serum metabolome. If replicated in larger studies, the altered metabolites might be considered as potential biomarkers in the generation of new hypotheses on the biological mechanisms behind obesity.

Keywords:
Lipid metabolism, Metabolite profile, Serum, Biomarker, Metabolomics, BMI, Childhood obesity
1.
Wang Y, Lobstein T: Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes 2006;1:11–25.
2.
Biro FM, Wien M: Childhood obesity and adult morbidities. Am J Clin Nutr 2010;91:S1499–S1505.
3.
Kiess W, Reich A, Müller G, Meyer K, Galler A, Bennek J, Kratzsch J: Clinical aspects of obesity in childhood and adolescence – diagnosis, treatment and prevention. Int J Obes Relat Metab Disord 2001;25(suppl 1):S75–79.
4.
Lloyd LJ, Langley-Evans SC, McMullen S: Childhood obesity and adult cardiovascular disease risk: a systematic review. Int J Obes 2010;34:18–28.
5.
Wang-Sattler R, Yu Y, Mittelstrass K, Lattka E, Altmaier E, Gieger C, Ladwig KH, Dahmen N, Weinberger KM, Hao P: Metabolic profiling reveals distinct variations linked to nicotine consumption in humans – first results from the KORA study. PLoS ONE 2008;3:e3863.
6.
Vinayavekhin N, Homan EA, Saghatelian A: Exploring disease through metabolomics. ACS Chem Biol 2010;5:91–103.
7.
Calvani R, Miccheli A, Capuani G, Tomassini Miccheli A, Puccetti C, Delfini M, Iaconelli A, Nanni G, Mingrone G: Gut microbiome-derived metabolites characterize a peculiar obese urinary metabotype. Int J Obes 2010;34:1095–1098.
8.
Suhre K, Meisinger C, Döring A, Altmaier E, Belcredi P, Gieger C, Chang D, Milburn MV, Gall WE, Weinberger KM, Mewes HW, Hrabé de Angelis M, Wichmann HE, Kronenberg F, Adamski J, Illig T: Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 2010;5:e13953.
9.
Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FGS, DeLany JP: Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 2010;18:1695–1700.
10.
Pietiläinen KH, Sysi-Aho M, Rissanen A, Seppänen-Laakso T, Yki-Järvinen H, Kaprio J, Oresic M: Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects–a monozygotic twin study. PLoS ONE 2007;2:e218.
11.
Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA: A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009;9:311–326.
12.
Kim JY, Park JY, Kim OY, Ham BM, Kim H-J, Kwon DY, Jang Y, Lee JH: Metabolic profiling of plasma in overweight/obese and lean men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC-Q-TOF MS). J Proteome Res 2010;9:4368–4375.
13.
Mihalik SJ, Michaliszyn SF, de Las Heras J, Bacha F, Lee S, Chace DH, Dejesus VR, Vockley J, Arslanian SA: Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. Diabetes Care 2012;35:605–611.
14.
Kromeyer-Hauschild K, Wabitsch M, Kunze D, Geller F, Geiß HC, Hesse V, Von Hippel A, Jaeger U, Johnsen S, Korte W: Perzentile für den Body-mass-Index für das Kindes-und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. Monatsschr Kinderheilkd 2001;149:807–818.
15.
Cole TJ, Bellizzi MC, Flegal KM, Dietz WH: Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000;320:1240–1243.
16.
Cole TJ: The LMS method for constructing normalized growth standards. Eur J Clin Nutr 1990;44:45–60.
17.
Marshall WA, Tanner JM: Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303.
18.
Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13–23.
19.
R Development Core Team: R: A language and environment for statistical computing. Vienna, R Foundation for Statistical Computing, 2009. www.R-project.org.
20.
Mevik BH, Wehrens R: The pls package: principal component and partial least squares regression in R. J Stat Softw 2007;18:1–24.
21.
Altmaier E, Ramsay SL, Graber A, Mewes H-W, Weinberger KM, Suhre K: Bioinformatics analysis of targeted metabolomics – uncovering old and new tales of diabetic mice under medication. Endocrinology 2008;149:3478–3489.
22.
Okada T, Furuhashi N, Kuromori Y, Miyashita M, Iwata F, Harada K: Plasma palmitoleic acid content and obesity in children. Am J Clin Nutr 2005;82:747–750.
23.
Houten SM, Wanders RJA: A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis 2010;33:469–477.
24.
Reinehr T, Kiess W, Andler W: Insulin sensitivity indices of glucose and free fatty acid metabolism in obese children and adolescents in relation to serum lipids. Metab Clin Exp 2005;54:397–402.
25.
Kim JY, Hickner RC, Cortright RL, Dohm GL, Houmard JA: Lipid oxidation is reduced in obese human skeletal muscle. Am J Physiol Endocrinol Metab 2000;279:E1039–1044.
26.
Ritov VB, Menshikova EV, Azuma K, Wood R, Toledo FGS, Goodpaster BH, Ruderman NB, Kelley DE: Deficiency of electron transport chain in human skeletal muscle mitochondria in type 2 diabetes mellitus and obesity. Am J Physiol Endocrinol Metab 2010;298:E49–58.
27.
Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JRB, Newgard CB, Lopaschuk GD, Muoio DM: Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008;7:45–56.
28.
Widhalm K, Zwiauer K, Hayde M, Roth E: Plasma concentrations of free amino acids during 3 weeks treatment of massively obese children with a very low calorie diet. Eur J Pediatr 1989;149:43–47.
29.
Tremblay F, Lavigne C, Jacques H, Marette A: Role of dietary proteins and amino acids in the pathogenesis of insulin resistance. Annu Rev Nutr 2007;27:293–310.
30.
Obici S, Wang J, Chowdury R, Feng Z, Siddhanta U, Morgan K, Rossetti L: Identification of a biochemical link between energy intake and energy expenditure. J Clin Invest 2002;109:1599–1605.
31.
Daniels MC, Ciaraldi TP, Nikoulina S, Henry RR, McClain DA: Glutamine:fructose-6-phosphate amidotransferase activity in cultured human skeletal muscle cells: relationship to glucose disposal rate in control and non-insulin-dependent diabetes mellitus subjects and regulation by glucose and insulin. J Clin Invest 1996;97:1235–1241.
32.
Patti ME, Virkamäki A, Landaker EJ, Kahn CR, Yki-Järvinen H: Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. Diabetes 1999;48:1562–1571.
33.
Engelmann B: Plasmalogens: targets for oxidants and major lipophilic antioxidants. Biochem Soc Trans 2004;32:147–150.
34.
Kelly AS, Jacobs DR, Sinaiko AR, Moran A, Steffen LM, Steinberger J: Relation of circulating oxidized LDL to obesity and insulin resistance in children. Pediatr Diabetes 2010;11:552–555.
35.
Levitan I, Volkov S, Subbaiah PV: Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal 2010;13:39–75.
36.
Christian AH, Mochari H, Mosca LJ: Waist circumference, body mass index, and their association with cardiometabolic and global risk. J Cardiometab Syndr 2009;4:12–19.
37.
Murugesan G, Sandhya Rani MR, Gerber CE, Mukhopadhyay C, Ransohoff RM, Chisolm GM, Kottke-Marchant K: Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines. J Mol Cell Cardiol 2003;35:1375–1384.
38.
Ma J, Folsom AR, Shahar E, Eckfeldt JH: Plasma fatty acid composition as an indicator of habitual dietary fat intake in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Clin Nutr 1995;62:564–571.
39.
Hodge AM, Simpson JA, Gibson RA, Sinclair AJ, Makrides M, O’Dea K, English DR, Giles GG: Plasma phospholipid fatty acid composition as a biomarker of habitual dietary fat intake in an ethnically diverse cohort. Nutr Metab Cardiovasc Dis 2007;17:415–426.
40.
Han JC, Lawlor DA, Kimm SYS: Childhood obesity. Lancet 2010;375:1737–1748.
41.
Holland WL, Summers SA: Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 2008;29:381–402.
42.
Hannun YA, Obeid LM: The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 2002;277:25847–25850.
43.
Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, Berglund L, Tall AR: Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000;20:2614–2618.
44.
Nelson JC, Jiang X-C, Tabas I, Tall A, Shea S: Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol 2006;163:903–912.
45.
Younsi M, Quilliot D, Al-Makdissy N, Delbachian I, Drouin P, Donner M, Ziegler O: Erythrocyte membrane phospholipid composition is related to hyperinsulinemia in obese nondiabetic women: effects of weight loss. Metab Clin Exp 2002;51:1261–1268.
46.
Felig P, Wahren J, Hendler R, Brundin T: Splanchnic glucose and amino acid metabolism in obesity. J Clin Invest 1974;53:582–590.
47.
Caballero B, Wurtman RJ: Differential effects of insulin resistance on leucine and glucose kinetics in obesity. Metab Clin Exp 1991;40:51–58.
48.
Chevalier S, Marliss EB, Morais JA, Lamarche M, Gougeon R: Whole-body protein anabolic response is resistant to the action of insulin in obese women. Am J Clin Nutr 2005;82:355–365.
49.
Pietiläinen KH, Naukkarinen J, Rissanen A, Saharinen J, Ellonen P, Keränen H, Suomalainen A, Götz A, Suortti T, Yki-Järvinen H, Oresic M, Kaprio J, Peltonen L: Global transcript profiles of fat in monozygotic twins discordant for BMI: pathways behind acquired obesity. PLoS Med 2008;5:e51.
50.
She P, Van Horn C, Reid T, Hutson SM, Cooney RN, Lynch CJ: Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. Am J Physiol Endocrinol Metab 2007;293:E1552–1563.
51.
Roemmich JN, Clark PA, Lusk M, Friel A, Weltman A, Epstein LH, Rogol AD: Pubertal alterations in growth and body composition. VI. Pubertal insulin resistance: relation to adiposity, body fat distribution and hormone release. Int J Obes Relat Metab Disord 2002;26:701–709.
52.
Hannon TS, Janosky J, Arslanian SA: Longitudinal study of physiologic insulin resistance and metabolic changes of puberty. Pediatr Res 2006;60:759–763.
53.
Arslanian SA, Kalhan SC: Protein turnover during puberty in normal children. Am J Physiol 1996;270:E79–84.
© 2012 S. Karger GmbH, Freiburg
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.